PD-RX Pharmaceuticals (PDRX) Stock Statistics & Valuation Metrics

PD-RX Pharmaceuticals has a market cap or net worth of $5.18M. The enterprise value is -$2.44M.

PD-RX Pharmaceuticals has 1,545,000 shares outstanding. The number of shares has decreased by -2.65% in one year.

PD-RX Pharmaceuticals’s return on equity (ROE) is -0.03 and return on invested capital (ROIC) is -4.28%.

The current PE Ratio of PD-RX Pharmaceuticals is ―. PD-RX Pharmaceuticals’s PEG ratio is 0.22.

In the last 12 months, PD-RX Pharmaceuticals had revenue of 18.35M and earned -257.52K in profits. Earnings per share was -0.17.

In the last 12 months, operating cash flow was ― and capital expenditures ―, giving a free cash flow of ― billion.

PD-RX Pharmaceuticals pays an annual dividend of $2.2, resulting in a dividend yield of ―

PD-RX Pharmaceuticals upcoming earnings date is ―, ―.

PD-RX Pharmaceuticals as a current ratio of 6.34, with Debt / Equity ratio of ―

In the past 12 months, PD-RX Pharmaceuticals has paid -21.22K in taxes.

PD-RX Pharmaceuticals EV to EBITDA ratio is 7.45, with an EV/FCF ratio of -3.20.

PD-RX Pharmaceuticals has ― in cash and marketable securities with ― in debt, giving a net cash position of ― billion.

Gross margin is ―, with operating margin of -2.60%, and net profit margin of -1.40%.

The average price target for PD-RX Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―